The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | 8-day versus 12-day manufactured bispecific LV20.19 CAR-Ts in B-NHL
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of a study evaluating the optimal manufacturing time for bispecific, tandem anti-CD20/anti-CD19 (LV20.19) CAR-Ts in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Overall, it appeared that a shorter manufacturing time led to a more naive CAR-T product, with higher complete response (CR) rates. This protocol was applied in a Phase I/II study evaluating this CAR-T product in R/R mantle cell lymphoma (MCL; NCT04186520). The trial reported an overall response rate (ORR) of 100%. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Miltenyi Biotec: Consultancy, Research Funding; Lilly Oncology: Consultancy, Honoraria; Epizyme: Consultancy; Bristol Myers Squibb: Consultancy; Incyte Corporation: Consultancy, Honoraria, Speakers Bureau; TG therapeutics: Consultancy; Kite Pharma: Consultancy.
